KRAS and malignant colon neoplasm: We treated SW620 human colon cancer cells (homozygous KRAS G12V) to assess the effect of TUS-007 on cetuximab-resistant cancer cells and demonstrated dose-dependent KRAS G12V degradation (Figure 4A).